Association Between Chronic Kidney Disease and Rates of Transfusion and Progression to End‐Stage Renal Disease in Patients Undergoing Transradial Versus Transfemoral Cardiac Catheterization—An Analysis From the Veterans Affairs Clinical Assessment Reporting and Tracking (CART) Program by Vora, Amit N. et al.
Association Between Chronic Kidney Disease and Rates of
Transfusion and Progression to End-Stage Renal Disease in
Patients Undergoing Transradial Versus Transfemoral Cardiac
Catheterization—An Analysis From the Veterans Affairs Clinical
Assessment Reporting and Tracking (CART) Program
Amit N. Vora, MD, MPH; Maggie Stanislawski, MS; Gary K. Grunwald, PhD; Mary E. Plomondon, PhD, MSPH; John S. Rumsfeld, MD, PhD; Thomas
M. Maddox, MD, MSc; Mladen I. Vidovich, MD; Walter Woody, MD; Brahmajee K. Nallamothu, MD; Hitinder S. Gurm, MD; Sunil V. Rao, MD
Background-—Patients with chronic kidney disease (CKD) are at increased risk for bleeding, transfusion, and dialysis after cardiac
catheterization. Whether rates of these complications are increased in this high-risk population undergoing transradial access
compared with transfemoral access is unknown.
Methods and Results-—From the Veterans Affairs (VA) Clinical Assessment Reporting and Tracking program, we identified 229 108
patients undergoing cardiac catheterization between 2007 and 2014, of which 48 155 (21.0%) had baseline glomerular filtration rate
(GFR) between 15 and 59 mL/min. We used multivariable Cox modeling to determine the independent association between
transradial access and postprocedure transfusion as well as progression to new dialysis by degree of renal dysfunction. Overall,
35 979 (15.7%) of patients underwent Transradial access. Transradial patients tended to be slightly younger, but, overall, had similar
rates of CKD compared to transfemoral patients (24.3% vs 27.1%). Transradial patients had longer fluoroscopy times (7.2 vs
6.0 minutes; P<0.001), but lower contrast use (85.0 vs 100.0 mL; P<0.001). The estimated rate of blood transfusion within 48 hours
was lower among transradial patients (0.85% vs 1.01%) as were rates of new dialysis at 1 year (0.58% vs 0.71%). After multivariable
adjustment, transradial access was associated with lower rates of progression to dialysis at 1 year overall (hazard ratio [HR], 0.83;
95% CI, 0.70–0.98), with no trend of increased risk for dialysis by degree of CKD compared with transfemoral access. Transradial
access was associated with greater reduction in transfusion rates with increasing degree of CKD (P value for trend=0.04: non-CKD:
HR, 0.99; 95% CI, 0.73–1.34; GFR 45–59 mL/min: HR, 0.93; 95% CI, 0.70–1.23; GFR 30–44 mL/min: HR, 0.73; 95% CI, 0.51–1.03;
GFR 15–29 mL/min: HR, 0.43; 95% CI, 0.20–0.90).
Conclusions-—Among patients undergoing cardiac catheterization in the VA health system, transradial access was associated with lower
risk for postprocedure transfusion within 48 hours among patients with more-severe CKD, and with lower risk of progression to end-
stage renal disease at 1 year compared with transfemoral access. These data provide additional evidence that transradial access may
provide significant benefit in this high-risk population. ( J Am Heart Assoc. 2017;6:e004819. DOI: 10.1161/JAHA.116.004819.)
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C hronic kidney disease (CKD) is common among patientswith coronary artery disease (CAD) and is independently
associated with increased risk for adverse cardiovascular and
renal outcomes.1–3 Clinical trials often exclude patients with
CKD because of their likelihood of suffering bleeding compli-
cations with antithrombotic therapy and progression to
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dialysis after cardiac catheterization.4 As such, evidence-
based approaches to patients with coexisting CKD and CAD
are lacking.
The risk for dialysis after cardiac catheterization can be
attributed to atheroemboli from aortic atherosclerosis,5–7
direct renal injury from iodinated contrast,8 or a combination
of these factors. The only accepted strategies to reduce the
incidence of renal injury are volume expansion andminimization
of contrast load.9 Similarly, the increased risk for bleeding in
patients with CKD may be attributed to reduced clearance of
antithrombotic agents, increased vascular calcification and
stiffness leading to vascular complications, or both.10 In this
context, the use of radial artery access for cardiac catheteri-
zation and percutaneous coronary intervention (PCI) is an
attractive strategy to reduce both the risk for bleeding and
dialysis, because the catheter avoids the abdominal aorta and
the radial artery is superficial and lends itself more easily to
hemostasis. On the other hand, it may be prudent to avoid radial
arterial access because the attendant damage to the artery can
increase the risk for radial artery occlusion and complicate the
placement of permanent dialysis access. Thus, the role of a
radial approach in patients with CKD remains unclear.
Accordingly, we used data from the Veterans Affairs (VA)
Clinical Assessment Reporting and Tracking (CART) program
to compare procedural characteristics, rates of blood trans-
fusion within 48 hours of cardiac catheterization, and
progression to new dialysis within 1 year in patients under-
going cardiac catheterization by the transradial and trans-
femoral approach, stratified by degree of renal dysfunction.
We hypothesized that patients undergoing transradial access
would have lower rates of transfusion within 48 hours, but
similar rates of progression to new dialysis by 1 year, with
greatest potential benefit observed in patients with more-
severe renal disease.
Methods
Data Sources
The Veterans Affairs (VA) Clinical Assessment Reporting and
Tracking (CART) program is a national clinical quality program
for all VA cardiac catheterization laboratories. It collects data
about catheterization procedures performed in all 78 VA
cardiac catheterization laboratories using a software applica-
tion that is embedded within the VA electronic medical
record, which then allows for data linkage in order to assess
short- and long-term longitudinal outcomes. Institutional
review board and VA research and development approvals
were obtained for the creation of the data set and for this
particular study. This study was approved by the Colorado
Multiple Institutional Review Board (COMIRB) with waiver of
informed consent, given the retrospective nature of the study.
The data elements included within the CART program are
standardized by the American College of Cardiology’s
National Cardiovascular Data Registry11 and include informa-
tion on procedural indications, demographic and clinical
characteristics, presentation details, procedures performed,
access site, periprocedural complications, and preprocedure
and intraprocedure medications. Continuous monitoring,
maintenance, and updating of the CART application are
performed by a dedicated staff, and the quality and integrity
of the data are maintained through the use of standardized
data definitions, uniform data transmission protocols, and
routine data quality checks and audits. Additional details of
the design and conduct of this registry have been previously
described.12–15
Study Population and Data Definitions
We studied all veterans undergoing cardiac catheterization for
any indication in the VA Health System between October 1,
2007 and September 30, 2014. Among the 261 274 patients
in the initial sample, we excluded patients with no information
about access site (N=2863), access site crossover (N=2134),
no administrative data for follow-up (N=41), past cardiac
transplant (N=1552), treated at sites with no transradial access
patients (N=1102), with estimated glomerular filtration rate
(eGFR) <15 mL/min (N=7477), those on dialysis at the time of
the catheterization (N=2877), and those with eGFR >59 mL/
min but a documented history of CKD (N=14 120). eGFR was
calculated using the abbreviated Modification of Diet in Renal
Disease equation,16 based on the most recent measured
creatinine before catheterization, which was ≤30 days before
the date of catheterization. We identified patients undergoing
cardiac catheterization by a transradial or transfemoral route.
Patients were stratified by degree of CKD into 4 categories
based on the National Kidney Foundation Kidney Disease
Outcomes Quality Initiative: ≥59 mL/min (no CKD), 45 to
59 mL/min (stage 3A), 30 to 44 mL/min (stage 3B), and 15 to
29 mL/min (stage 4).
Outcomes of Interest
The primary clinical events of interest were the occurrence of
blood transfusion within 48 hours and progression to dialysis
within 1 year of the index catheterization. Blood transfusion
was used as a surrogate for bleeding complications given that
bleeding events in CART are not adjudicated. Progression to
new dialysis was assessed by dialysis procedures recorded in
VA administrative and fee-based data sources after the date
of the catheterization through September 2014. Because
outcomes were censored for some patients, we used survival
methods that account for censoring in the analysis, as
described below.
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Statistical Analysis
We compared baseline demographic, clinical, and presenta-
tion characteristics between patients undergoing cardiac
catheterization by a transradial versus a transfemoral
approach. Continuous variables are expressed as median
values with 25th and 75th percentiles whereas categorical
values are presented as percentages. We used Pearson chi-
squared tests for categorical variables and Wilcoxon rank-sum
tests for continuous variables.
We compared the unadjusted rates of each outcome of
interest using cumulative incidence plots, estimated event
rates, and Gray’s test, accounting for both censoring and
death as a competing risk. We then used Cox proportional
hazards modeling with a robust covariance estimator to
account for correlation by hospital in order to determine the
independent association between transradial access and
postprocedure transfusion as well as progression to new
dialysis, using transfemoral as the reference. We modeled this
relationship between access site and the outcomes with and
without an interaction term between access site and degree
of CKD and evaluated the trend across degree of CKD using
type 3 tests in the SAS Phreg procedure. The outcomes were
adjusted for the following variables: demographics (age, sex,
race, Hispanic ethnicity, and obesity); medical history (hyper-
tension, hyperlipidemia, diabetes mellitus, tobacco use,
chronic obstructive pulmonary disease [COPD], peripheral
artery disease [PAD], past myocardial infarction [MI], past
cardiac transplant, past coronary artery bypass surgery
[CABG], congestive heart failure [CHF], cerebrovascular
disease, post-traumatic stress disorder [PTSD], depression,
obstructive sleep apnea); anemia; and presence of cardio-
genic shock or heart failure on admission.
We performed a sensitivity analysis in which we repeated
the Cox models comparing the risk of the outcomes for
transradial access relative to transfemoral access in the
subset of patients with both ad-hoc PCI and nonmissing
contrast volume (N=47 412). We performed another sensi-
tivity analysis restricting the study population to sites
performing transradial access in at least 5% of patients.
Additionally, we sought to explore whether the association
between access site and progression to dialysis was mediated
by the decrease in transfusion among patients undergoing
transradial access.17 We performed the 4-step mediation
analysis developed by Baron and Kenney using similar Cox
proportional hazards models to those described above.18
A P value of 0.05 was considered statistically significant.
All statistical analyses were performed by the CART Coordi-
nating Center at the Denver VA Medical Center using SAS
(version 9.4; SAS Institute Inc., Cary, NC) and R software
(version 3.2.2; R Foundation for Statistical Computing, Vienna,
Austria). The study was approved by the COMIRB.
Results
Between 2007 and 2014, 261 274 patients underwent
cardiac catheterization. After applying exclusions, the final
study sample consisted of 229 108 patients at 78 cardiac
catheterization facilities across the VA Health System, of
which 35 979 (15.7%) underwent catheterization by transra-
dial access (Figure 1). Baseline characteristics for the 2
groups are listed in Table 1. Transradial access patients were
younger, more likely African American, and more likely obese,
but had lower rates of past cardiac events and procedures
compared to transfemoral access patients; most differences
were statistically significant but clinically modest. Patients
with past cardiac procedures were less likely to undergo
catheterization by a transradial route. Transradial patients had
longer fluoroscopy times (7.2 vs 6.0 minutes; P<0.001), but
lower contrast use (85.0 vs 100.0 mL; P<0.001). When
stratified by degree of CKD, transradial access patients were
less likely to have stage 3B or 4 CKD than transfemoral
patients: no CKD: 80.5% versus 78.7%; GFR 45 to 59 mL/min:
14.8% versus 15.5%; GFR 30 to 44 mL/min: 4.1% versus
4.9%; GFR 15 to 29 mL/min: 0.6% versus 0.9% (P<0.001);
however, overall differences were modest. Rates of transradial
versus transfemoral access are described in Table S1.
Rates of Blood Transfusion Within 48 Hours and
Progression to New Dialysis During Follow-up
The cumulative incidence curve for the rate of blood
transfusion within 48 hours is shown in Figure 2. The
estimated rate of blood transfusion within 48 hours of cardiac
catheterization was 0.99% (95% CI, 0.94–1.02); it was 0.85%
(95% CI, 0.75–0.94) among those who underwent catheter-
ization by transradial access and 1.01% (95% CI, 0.96–1.05)
by transfemoral access (P=0.004). Within each access
category, transfusion rates were higher among patients with
more-advanced CKD (Table 2).
The cumulative incidence curve for the progression to
dialysis at 1 year is shown in Figure 2. An estimated 0.69%
(95% CI, 0.65–0.72) of patients progressed to new dialysis
during the follow-up period. Unadjusted rates of progression to
dialysis were slightly lower among transradial patients (0.58%;
95% CI, 0.50–0.65 vs 0.71%; 95% CI, 0.67–0.75; P=0.005) and
increased with increasing severity of CKD for both groups.
Multivariable Analyses
We performed Cox proportional hazards modeling to compare
risks of blood transfusion and progression to new dialysis
between patients undergoing catheterization by each access
strategy. For each outcome, we tested the interaction between
transradial access and degree of CKD, and the trend in
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association of transradial with outcomes by degree of CKD.
After multivariable adjustment, transradial access was asso-
ciated with decreasing rates of blood transfusion within
48 hours with increasing severity of CKD, with significant
association only for patients with most-severe CKD (P value for
trend=0.04; no CKD: hazard ratio [HR]=0.99; 95% CI, 0.73–
1.34; GFR 45–59 mL/min: HR=0.93; 95% CI, 0.70–1.23; GFR
30–44 mL/min: HR=0.73; 95% CI, 0.51–1.03; GFR 15–
29 mL/min: HR=0.43; 95% CI, 0.20–0.90; Figure 3). Combin-
ing all patients, risk of transfusion did not differ significantly by
access site (HR, 0.91; 95% CI, 0.72–1.15; P=0.44), but among
CKD patients only, risk for transfusion was lower among
transradial patients (HR, 0.79; 95% CI, 0.64–0.98; P=0.03).
Among all patients undergoing cardiac catheterization, risk
of progression to end-stage renal disease (ESRD) within 1 year
was lower among patients undergoing transradial access (HR,
0.83; 95% CI, 0.70–0.98; P=0.03) and was similar when
restricted only to patients with CKD (HR, 0.80; 95% CI, 0.68–
0.94; P=0.008). The benefit of transradial access did not vary
significantly with degree of CKD, nor was there a significant
trend by degree of CKD (P value for interaction=0.15; P value
for trend=0.08), although the HRs were lowest among those
with the most-severe CKD (no CKD: HR=0.89; 95% CI, 0.69–
1.15; GFR 45–59 mL/min: HR=1.1; 95% CI, 0.83–1.48; GFR
30–44 mL/min: HR=0.78; 95% CI, 0.58–1.05; GFR 15–
29 mL/min: HR=0.69; 95% CI, 0.51–0.94; Figure 3).
In sensitivity analysis, after adjusting for contrast volume
and excluding patients who did not undergo ad-hoc PCI,
similar trends were observed with respect to blood transfu-
sion and progression to dialysis (Table S2). After repeating the
analysis excluding 28 sites performing transradial access in
<5% of patients, results similar to those in the primary
analysis were observed (Table S3). We also excluded patients
with a history of past CABG (Table S4) and demonstrated
results similar to those in the primary analysis. To explore the
mediating effect of lower transfusion rates among transradial
access patients in progression to dialysis, we adjusted for
transfusions as a potential intermediary mechanism in the
model of progression to dialysis. After adjustment, the HR for
access site (transradial vs transfemoral) was 0.81 (95% CI,
0.67–0.96; P=0.01), with the occurrence of transfusion within
48 hours being independently associated with dialysis (HR,
2.97; 95% CI, 2.26–3.92; P<0.001), suggesting that although
bleeding was associated with higher risk for dialysis, the
reduction in bleeding with transradial access did not seem to
be the mediator of the decreased risk for dialysis with
transradial access.
Discussion
In this large, national sample of veterans undergoing cardiac
catheterization, we observed that transradial access was
261,274  diagnosc cath procedures
From 10/2007 – 9/2014 at 78 sites
32,166 were excluded
2,863 with no access site informaon
2,134 with access site crossover
41 with no administrave follow-up data
1,552 prior cardiac transplant
1,102 site only performs transfemoral access
7,477 with eGFR <15 ml/min
2,877 on dialysis at me of catheterizaon
14,120 with eGFR >59ml/min but history of CKD
229,108 paents 
At 78 sites
193,129 Paents Undergo 
Transfemoral access
35,979 Paents Undergo
Transradial access
Figure 1. Study population characteristics. This figure displays the study population characteristics,
including exclusions. CKD indicates chronic kidney disease; eGFR, estimated glomerular filtration rate.
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associated with: (1) slightly increased fluoroscopy times yet
no increased used in contrast; (2) significantly lower rates of
blood transfusion within 48 hours among patients with CKD,
with increasing observed benefit with increasing severity of
renal dysfunction; and (3) lower rates of progression to
dialysis at 1 year, particularly among patients with severe
CKD, compared with transfemoral access; this effect was not
mediated by the decreased bleeding with transradial access.
Therefore, the results of this study suggest that transradial
access is associated with lower risk of periprocedural
Table 1. Baseline Characteristics*
Overall (N=229 108) Transradial Access (n=35 979) Transfemoral Access (n=193 129)
Demographics
Age in y, median (IQR) 64 (59–70) 64 (59–68) 64 (60–70)
Male 97.0 96.8 97.0
Race
White 79.2 74.8 80.0
Black 13.9 18.1 13.1
Other 6.9 7.1 6.9
Hispanic 4.7 3.6 4.9
BMI, median (IQR) 29.9 (26.4–34.0) 30.3 (26.7–35.1) 29.8 (26.4–33.9)
Past medical history
Past MI 32.7 30.2 33.1
Past CHF 26.4 25.0 26.6
Past CVA 16.1 15.6 16.2
Past PCI 32.4 30.0 32.8
Past CABG 21.8 11.7 23.7
Hypertension 88.2 89.4 88.0
Diabetes mellitus 45.2 46.3 45.0
Dyslipidemia 86.5 86.7 86.5
PAD 18.4 20.4 18.1
COPD 22.2 21.4 22.4
PTSD 17.4 20.8 16.7
Depression 31.5 33.2 31.1
Sleep apnea 20.8 25.1 20.0
Presenting features
Acute coronary syndrome 20.3 18.6 20.6
Heart failure 6.0 5.6 6.1
Cardiogenic shock within 24 hours
Systolic BP on presentation 132 (123–141) 133 (124–142) 132 (123–141)
Heart rate on presentation 69 (61–80) 70 (62–80) 69 (61–79)
Hemoglobin, g/dL 13.7 (12.5–14.7) 13.7 (12.5–14.7) 13.8 (12.6–14.8)
Creatinine 1.0 (0.9–1.2) 1.0 (0.9–1.2) 1.0 (0.9–1.2)
Procedural features
Fluoroscopy time 6.1 (3.5–11.2) 7.2 (4.4–12.3) 6.0 (3.3–11.0)
Contrast volume, mL 100 (70–136) 85.0 (60.0–125.0) 100 (70–140)
LV ventriculography 38.7 33.8 39.6
BMI indicates body mass index; BP, blood pressure; CABG, coronary artery bypass graft surgery; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVA,
cerebrovascular accident; IQR, interquartile range; LV, left ventricular; MI, myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; PTSD, post-
traumatic stress disorder.
*Data are expressed as percentage of patients for categorical variables, median (interquartile range) for continuous variables.
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bleeding in CKD patients with greatest benefit in patients with
severe CKD. Additionally, rates of progression to ESRD appear
to be lower among transradial patients. These data suggest
that transradial may be safer in patients with CKD; however,
prospective, randomized trials in this population are needed
to confirm our observational findings.
Acute kidney injury (AKI) attributed to contrast-induced
nephropathy is a known complication of cardiac catheteriza-
tion, and the risk of AKI is directly related to the degree of
CKD before catheterization, amount of contrast used during
the procedure, and past burden of atheroemboli in the aorta.
We found slightly lower overall usage of contrast in patients
undergoing catheterization by transradial access. Whereas the
overall difference in contrast usage between the transradial
and transfemoral patients is modest and clinically similar,
previous studies have reported varying levels of contrast use
during transradial procedures.19,20 Importantly, patients
undergoing transradial access were less likely to have past
CABG (and thus require coronary bypass angiography) and
also less likely to undergo left ventriculography. Nevertheless,
our data provide some reassurance that transradial catheter-
ization may not worsen CKD attributed to a higher volume of
contrast during the procedure.
Clinically significant bleeding events are among the most
common complications post-PCI and have significant down-
stream consequences, including increased rates of stroke,
nonfatal MI, and short- and long-term mortality. Although
estimates of major bleeding complications vary widely in the
literature, depending on the specific population and the
precise definition,21–24 more-recent estimates have placed
the rate of major bleeding events at less than 5%, a decrease
that has been attributed to better periprocedural anticoagu-
lation and transradial access. CKD has consistently been
shown to be a major risk factor for bleeding across clinical
trials and registries.25,26 Indeed, rates of bleeding among
patients with CKD undergoing PCI have been reported to be
even higher compared to patients without CKD. Saltzman
et al noted an almost 3-fold higher rate of major bleeding
(19.3% vs 6.7%; P<0.001) among patients presenting with ST-
elevation myocardial infarction (STEMI) undergoing PCI in the
HORIZONS-AMI (heparin plus a glycoprotein IIb/IIIa inhibitor
versus bivalirudin monotherapy and paclitaxel-eluting stents
versus bare-metal stents in acute myocardial infarction)
trial.27 In the non-ST-elevation myocardial infarction popula-
tion, an analysis using the ACTION Registry—Get With the
Guidelines noted that patients with stage 3 to 5 CKD had 2- to
6-fold increased unadjusted risk of major bleeding compared
to patients with an eGFR ≥60 mL/min per 1.73 m2, a
difference that was attenuated, but persisted, after multivari-
able adjustment.27 Randomized trial data19,28 as well as large-
scale registry data29 have described the significant reduction
in major bleeding with transradial access compared with
transfemoral access. Our study confirms and extends those
findings in a number of ways. We report significantly lower
bleeding rates among patients with CKD. Additionally, we
demonstrate lower bleeding with a directional trend toward
increased benefit in patients with the most-severe CKD, a
population that is at highest baseline risk of significant
bleeding. These results suggest that the benefit of transradial
access may be greatest in patients at highest risk of bleeding,
which is a novel finding. Nevertheless, the benefits in major
bleeding with transradial access need to be weighed against
the overall risk of progression to ESRD, a situation in which
preservation of potential access sites for dialysis is of primary
importance. We report that an estimated 0.69% of patients
progressed to new dialysis within 1 year, with lower rates
among transradial versus transfemoral patients (0.58% vs
0.71%; P=0.005). There was a clear relationship between
degree of renal insufficiency and progression to new dialysis,
with 19.6% of patients with stage 4 CKD (GFR 15–29 mL/
min) progressing to new dialysis, but only 1.0% of patients
with stage 3A CKD (GFR 45–59 mL/min). There is concern
that transradial access may damage the radial artery, making
it potentially unusable for subsequent arteriovenous fistula
(AVF) creation. Previous studies have noted increased
inflammation by the introducer sheath30 and thrombus
Figure 2. Cumulative incidence of reported outcomes. This figure displays the cumulative incidence of
(A) blood transfusion within 48 hours and (B) progression to dialysis at 1 year.
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formation, and optical coherence tomography of accessed
vessels have demonstrated intimal tears, medial dissections,
and the formation of microthrombi.31 Although our data do
not describe rates of access-site complications that may
complicate radiocephalic AVF creation, previous studies have
underscored the risk of radial artery occlusion (RAO). The risk
for RAO can be minimized with low-profile equipment,
adequate anticoagulation, prevention of radial artery spasm,
and use of nonocclusive hemostasis after transradial proce-
dures. These strategies have been shown to reduce RAO rates
to 0.1% to 1.5%.32 Additionally, difficulty with radiocephalic
AVF creation typically is attributed to complications with the
cephalic vein, not the radial artery.33 These data, as well as
our findings, should be taken into account when selecting an
access site in CKD patients undergoing cardiac catheteriza-
tion or PCI.
Our study must be considered in the context of several
important limitations. First, our data only captured rates of
transfusion within 48 hours after cardiac catheterization and
do not capture actual rates of major or minor bleeding. It is
possible that there is heterogeneity in individual providers’
threshold for administering a transfusion.34 Nevertheless,
large studies have described worse outcomes post-PCI in
patients that have required transfusion.35 Next, our data only
describe progression to new dialysis at 1 year; it is likely that
risk of developing worsening renal disease increases over
time. Nevertheless, given the safety profile of transradial
access with respect to bleeding, it would seem reasonable to
consider a strategy that minimizes a known complication
given the theoretical risk of challenging AVF creation further
into the future. Third, we do not have systematic data on
access site complications with either transfemoral or
transradial access. We also do not have data regarding
possible increased difficulty with creating a radiocephalic AVF
after transradial access. Fourth, we did not capture right
radial versus left radial access, which may have affected the
total amount of fluoroscopy time and contrast usage among
transradial patients. We also did not collect operator expe-
rience, which also may have affected our findings. Addition-
ally, access-site selection was not random, and there is the
possibility that the observed benefit associated with transra-
dial access was attributed to patient selection factors and not
access route. Specifically, we do not have information on
whether the patient present with STEMI, the patient popula-
tion for which strong evidence exists regarding the superiority
of transradial access. Because patients undergoing transradial
access were less likely to have a past history of CABG and
also less likely to undergo left ventriculography, lower use of
contrast during the procedure may be affected by these
factors more than the actual access site. Our sensitivity
analyses adjusted for contrast use and did not demonstrate a
significant change in the overall results. Finally, because thisTa
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is an observational analysis, we cannot draw causal infer-
ences from these results, and we cannot exclude the
possibility of unmeasured confounding.
Conclusions
Among patients undergoing cardiac catheterization in the VA
health system, transradial access was associated with greater
reduction in postprocedure transfusion within 48 hours with
increasing severity of CKD and less progression to ESRD at
1 year. These data provide additional evidence that transra-
dial access may provide significant benefit in this high-risk
population and may be considered when selecting an access
site for CKD patients undergoing PCI; however, prospective,
randomized trials in this population are needed to confirm our
observational findings.
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SUPPLEMENTAL MATERIAL 
 
Table S1. Rates of Transradial versus Transfemoral Access by degree of renal dysfunction 
GFR 
(ml/min) 
Total 
patients TR patients TF patients %TR %TF 
45-59 35207 5315 29892 15.1% 84.9% 
30-44 10976 1485 9491 13.5% 86.5% 
15-29 1972 232 1740 11.8% 88.2% 
Abbreviations: GFR, glomerular filtration rate; TF, transfemoral; TR, transradial 
Table S2. After adjustment for contrast use and excluding patients undergoing same-day PCI 
  Adjusted* 
Outcome 
Total N for 
Model Comparison HR 
Lower 
CL 
Upper 
CL 
P-
value 
ESRD  No CKD 1.01 0.543 1.876 0.977 
    45-59 1.46 0.729 2.906 0.287 
    30-44 0.45 0.156 1.274 0.131 
    15-29 0.59 0.23 1.533 0.281 
  47412 All patients 0.75 0.517 1.08 0.122 
Major 
Bleeding  No CKD 0.58 0.392 0.868 0.008 
    45-59 0.57 0.281 1.174 0.128 
    30-44 0.65 0.312 1.365 0.257 
    15-29 1.01 0.27 3.743 0.994 
  47412 All patients 0.6 0.416 0.865 0.006 
Abbreviations: CKD, chronic kidney disease; CL, confidence limit; ESRD, end-stage renal 
disease 
Table S3. After excluding sites (n=28) with <5% transradial use 
      Adjusted 
Outcome 
Total N for 
Model Comparison HR 
Lower 
CL 
Upper 
CL 
P-
value 
ESRD  No CKD 0.93 0.712 1.223 0.616 
    45-59 1.1 0.796 1.512 0.57 
    30-44 0.85 0.629 1.143 0.278 
    15-29 0.72 0.532 0.985 0.04 
  161881 All patients 0.84 0.706 1 0.05 
Major 
Bleeding  No CKD 0.97 0.712 1.312 0.826 
    45-59 0.9 0.661 1.235 0.526 
    30-44 0.65 0.447 0.941 0.023 
    15-29 0.4 0.175 0.899 0.027 
  161881 All patients 0.88 0.69 1.122 0.303 
Abbreviations: CKD, chronic kidney disease; CL, confidence limit; ESRD, end-stage renal 
disease 
Table S4. Excluding patients with prior CABG 
      Adjusted 
Outcome 
Total N for 
Model Comparison HR 
Lower 
CL 
Upper 
CL 
P-
value 
ESRD   No CKD 0.92 0.707 1.189 0.513 
    45-59 1.03 0.733 1.438 0.878 
    30-44 0.79 0.566 1.099 0.161 
    15-29 0.68 0.497 0.939 0.019 
  179123 All patients 0.83 0.692 1.001 0.052 
Major 
Bleeding   No CKD 0.95 0.713 1.276 0.75 
    45-59 0.93 0.685 1.257 0.629 
    30-44 0.73 0.5 1.073 0.11 
    15-29 0.33 0.123 0.855 0.023 
  179123 All patients 0.89 0.708 1.118 0.317 
Abbreviations: CABG, coronary artery bypass grafting; CKD, chronic kidney disease; CL, 
confidence limit; ESRD, end-stage renal disease 
 
